vinpocetine has been researched along with Atherogenesis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y; Li, JD; Yan, C | 1 |
| Fan, F; Li, H; Li, S; Lu, Y; Peng, W; Wang, K; Xu, Y; Zhuang, J | 1 |
| Yang, L; Zhang, L | 1 |
1 review(s) available for vinpocetine and Atherogenesis
| Article | Year |
|---|---|
Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: a review of the literature.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Brain Ischemia; Humans; Stroke; Vinca Alkaloids | 2014 |
2 other study(ies) available for vinpocetine and Atherogenesis
| Article | Year |
|---|---|
Vinpocetine attenuates lipid accumulation and atherosclerosis formation.
Topics: Animals; Atherosclerosis; Cell Line; Dietary Fats; Fluorescent Antibody Technique; Lipid Metabolism; Lipoproteins, LDL; Macrophages; Mice; Mice, Knockout; Scavenger Receptors, Class E; Vinca Alkaloids | 2013 |
Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cyclic Nucleotide Phosphodiesterases, Type 1; Disease Models, Animal; Disease Progression; Foam Cells; Humans; I-kappa B Proteins; Inflammation; Lipoproteins, LDL; Male; Mice; Mice, Knockout; Monocytes; NF-kappa B; Oxidative Stress; Phosphorylation; Plaque, Atherosclerotic; Proto-Oncogene Proteins c-akt; Signal Transduction; Vinca Alkaloids | 2013 |